Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPEP | Q07075 | 9/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CPA1 | P15085 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.37 |
| ▸ | FNTB | P49356 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13154778 | 0.95 | ENPEP (0.49) | ENPEPALDH1A1METAP2METAP1L3MBTL1 | |
| SCHEMBL14941274 | 0.95 | ENPEP (0.49) | ENPEPALDH1A1METAP2METAP1L3MBTL1 | |
| SCHEMBL14941273 | 0.95 | ENPEP (0.49) | ENPEPALDH1A1METAP2METAP1L3MBTL1 | |
| SCHEMBL30051191 | 0.92 | ENPEP (0.47) | ENPEPALDH1A1L3MBTL1 | |
| SCHEMBL30051524 | 0.90 | MME (0.46) | ENPEPMETAP2METAP1MMEACE | |
| SCHEMBL30051389 | 0.90 | FNTA (0.46) | ENPEPALDH1A1L3MBTL1FNTAFNTB | |
| SCHEMBL30051929 | 0.88 | ENPEP (0.44) | ENPEPALDH1A1L3MBTL1FNTAFNTB | |
| SCHEMBL30051796 | 0.88 | FNTA (0.43) | ALDH1A1METAP2METAP1BACE1FNTA | |
| SCHEMBL2373394 | 0.88 | BACE1 (0.48) | ENPEPBACE1 | |
| SCHEMBL30051213 | 0.87 | FNTA (0.44) | ENPEPALDH1A1FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ENPEP 18/4885ALDH1A1 3596/4885METAP2 695/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | ENPEP 5/4885ALDH1A1 4110/4885METAP2 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.